Blau Farmaceutica SA
BOVESPA:BLAU3
Blau Farmaceutica SA
BOVESPA:BLAU3
Price:
11.6
BRL
0.69%
Market Closed
Market Cap:
R$2.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Blau Farmaceutica SA
BOVESPA:BLAU3
|
BR |
|
Caterpillar Inc
NYSE:CAT
|
US |
Balance Sheet
Balance Sheet Decomposition
Blau Farmaceutica SA
Blau Farmaceutica SA
Balance Sheet Decomposition is not available for
Blau Farmaceutica SA
Blau Farmaceutica SA
Balance Sheet
Blau Farmaceutica SA
Blau Farmaceutica SA
Currency: BRL
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
10
|
10
|
13
|
11
|
6
|
70
|
52
|
14
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
70
|
0
|
0
|
|
| Cash Equivalents |
10
|
10
|
13
|
11
|
6
|
0
|
52
|
14
|
|
| Short-Term Investments |
0
|
0
|
0
|
102
|
153
|
144
|
871
|
630
|
|
| Total Receivables |
0
|
107
|
114
|
172
|
155
|
259
|
345
|
465
|
|
| Accounts Receivables |
0
|
99
|
104
|
163
|
141
|
248
|
332
|
421
|
|
| Other Receivables |
0
|
9
|
10
|
9
|
14
|
11
|
14
|
45
|
|
| Inventory |
0
|
104
|
119
|
145
|
188
|
327
|
417
|
569
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
11
|
0
|
|
| Total Current Assets |
0
|
222
|
246
|
430
|
501
|
800
|
1 696
|
1 678
|
|
| PP&E Net |
0
|
72
|
100
|
136
|
194
|
257
|
393
|
558
|
|
| PP&E Gross |
0
|
72
|
100
|
136
|
194
|
257
|
393
|
558
|
|
| Accumulated Depreciation |
0
|
44
|
51
|
60
|
66
|
82
|
99
|
102
|
|
| Intangible Assets |
0
|
3
|
2
|
2
|
14
|
26
|
56
|
91
|
|
| Goodwill |
0
|
7
|
7
|
7
|
7
|
145
|
143
|
143
|
|
| Note Receivable |
0
|
9
|
6
|
8
|
6
|
23
|
34
|
22
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
3
|
4
|
12
|
16
|
22
|
7
|
7
|
|
| Other Assets |
0
|
7
|
7
|
7
|
7
|
145
|
143
|
143
|
|
| Total Assets |
0
N/A
|
315
N/A
|
366
+16%
|
594
+62%
|
738
+24%
|
1 273
+72%
|
2 328
+83%
|
2 499
+7%
|
|
| Liabilities | |||||||||
| Accounts Payable |
0
|
46
|
76
|
86
|
85
|
133
|
116
|
164
|
|
| Accrued Liabilities |
0
|
13
|
16
|
16
|
18
|
30
|
55
|
57
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
108
|
103
|
32
|
75
|
63
|
94
|
84
|
|
| Other Current Liabilities |
0
|
14
|
28
|
39
|
84
|
137
|
78
|
67
|
|
| Total Current Liabilities |
0
|
181
|
222
|
174
|
263
|
364
|
343
|
371
|
|
| Long-Term Debt |
0
|
34
|
1
|
193
|
204
|
627
|
281
|
228
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
18
|
35
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
|
| Other Liabilities |
0
|
3
|
5
|
5
|
6
|
61
|
51
|
47
|
|
| Total Liabilities |
0
N/A
|
218
N/A
|
228
+4%
|
371
+63%
|
473
+27%
|
1 051
+122%
|
692
-34%
|
677
-2%
|
|
| Equity | |||||||||
| Common Stock |
0
|
56
|
57
|
101
|
101
|
101
|
1 317
|
1 317
|
|
| Retained Earnings |
0
|
35
|
77
|
124
|
167
|
119
|
325
|
563
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
40
|
|
| Other Equity |
0
|
6
|
5
|
1
|
2
|
2
|
5
|
17
|
|
| Total Equity |
0
N/A
|
97
N/A
|
138
+42%
|
223
+61%
|
266
+19%
|
221
-17%
|
1 636
+639%
|
1 822
+11%
|
|
| Total Liabilities & Equity |
0
N/A
|
315
N/A
|
366
+16%
|
594
+62%
|
738
+24%
|
1 273
+72%
|
2 328
+83%
|
2 499
+7%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
192
|
192
|
192
|
192
|
192
|
192
|
233
|
231
|
|
Switch to:
Switch to:
See Also
Discover More
